CRAT

Across TCGA pan-cancer cohorts, CRAT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRAT data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRAT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRAT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where CRAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.906	0.427	.019	16	view →
LSCC	DFS	Quartile	All	0.910	1.000	.014	4	view →
HNSC	DFS	Median	All	0.715	0.840	.033	4	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
GBM	OS	Median	All	0.393	0.626	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRAT–CCRCC (DFS)

Open the CCRCC breakdown →